The elevated risk of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM) is well established, however, development of these comorbidities from T2DM diagnosis over an extended time period has not been adequately studied. We estimated the cumulative incidence of CVD in T2DM over the course of 15 years in a large U.S. integrated healthcare delivery system. The study population included adult T2DM patients diagnosed between 1/1/2003 and 12/31/2014 based on validated algorithms using the electronic health record (EHR). Patients were followed from 6 months after their T2DM diagnosis date through 6/30/2018. Patient demographics, CVD risk factors, medical history, and medication use were ascertained from the EHR. The cumulative incidence of myocardial infarction (MI), heart failure (HF) and all-cause mortality was estimated separately at 2, 5, 10, 13 and 15 years among the patients who did not have a prior history of each condition (at-risk population) using the Kaplan-Meier method. We identified 135,199 patients newly diagnosed with T2DM. Mean (SD) age was 58 (13) years, 48% were female, 36% were white, 35% Hispanic, 12% black, and 12% Asian. Median follow-up was 6 years. At baseline, 1.3% had MI and 3.5% had HF. By 15 years following T2DM diagnosis, 30.0% of the cohort died, 7.6% had MI and 11.5% HF. The 2-, 5-, 10-, 13-, and 15-year cumulative incidence among the population-at-risk are shown in the Table.
J. An: Research Support; Self; Merck & Co., Inc. G.A. Nichols: Research Support; Self; Amarin Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Scientific Affairs, LLC., Merck Sharp & Dohme Corp. L. Qian: None. R. Wei: None. T. Harrison: None. M.A. Munis: None. Z. Li: None. T. Weiss: Employee; Self; Merck & Co., Inc. K. Iglay: Employee; Self; Merck & Co., Inc. Stock/Shareholder; Self; Merck & Co., Inc. S. Rajpathak: None. K. Reynolds: Research Support; Self; Amarin Corporation, Amgen Inc., Merck Sharp & Dohme Corp., Novartis AG.
